Antibody Pair Development Service for Sandwich ELISA & Lateral Flow Assays

An antibody pair usually includes a capture antibody and a detection antibody. In a sandwich ELISA, the capture antibody binds the target antigen first, while the detection antibody binds another accessible epitope on the same antigen to generate the measurable signal.

For the pair to work, the two antibodies must recognize compatible, non-overlapping epitopes. If they compete for the same binding site or interfere with each other, the assay may produce weak signal, high background, or poor sensitivity.

Yes. Boster can develop matched antibody pairs for the same target and evaluate candidate antibodies for capture and detection compatibility. The workflow may include antigen design, immunization, antibody generation, pair screening, recombinant protein standard preparation, and assay-format validation.

The final strategy depends on the target antigen, species, assay format, sample type, and required performance metrics.

You may provide your own antigen if it is already available and suitable for immunization and screening. If not, Boster can help design and produce recombinant protein or other antigen formats based on your target and assay requirements.

Antigen design is especially important for native-state immunoassays, membrane proteins, glycoproteins, modified proteins, and targets where epitope accessibility affects assay performance.

Price comparison should look beyond the initial quote. A lower-cost project may become expensive if the delivered antibodies do not pair effectively, require repeated screening, or cannot support your intended assay format.

When comparing providers, check whether the quote includes antigen design, recombinant protein production, antibody generation, pairing validation, epitope analysis, standard curve testing, QC documentation, and scale-up support.

For suitable RUO targets, Boster custom antibody development starts at $1,300 per antibody. Final pricing depends on target complexity, antigen format, screening depth, and validation requirements.

A typical antibody pair development project requires approximately 5–8 months from project initiation to delivery of validated antibody pairs. This timeline may include antigen production, immunization, immune response maturation, clone screening, pairing validation, final antibody production, and QC documentation.

Timeline variations depend on antigen complexity, whether antigen production is required, the selected antibody strategy, and the depth of validation needed for your assay.

Yes. Boster can support challenging antigen classes including membrane proteins, glycoproteins, modified proteins, low-abundance biomarkers, and targets with limited commercial antibody availability.

For difficult targets, antigen format and screening design are critical. Depending on the project, strategies may include extracellular domains, recombinant fragments, peptides, modified antigen formats, or other approaches designed to improve epitope accessibility and pair discovery.

Standard deliverables may include purified antibodies, recommended pair combinations, pairing validation data, recombinant protein standard information, standard curve data, specificity testing, sensitivity assessment, linear range evaluation, signal-to-background analysis, and recommended assay conditions.

Depending on project scope, additional documentation may include affinity measurements, epitope mapping or binning information, batch-to-batch consistency data, stability testing, and scale-up documentation.

Yes. Boster can support downstream scale-up planning and reagent supply based on project requirements. For clients moving from discovery to assay development or commercialization, documentation and manufacturing considerations can be discussed during project planning.

Available support may include production planning, QC method guidance, batch consistency testing, and technical support for downstream assay optimization.

Pairing-focused screening is designed to reduce the risk of pair failure, but some targets remain challenging. If initial screening does not identify a pair that meets your specifications, Boster can review potential causes such as antigen format, epitope accessibility, immune response quality, screening stringency, or assay conditions.

Based on the review, the project may be adjusted through alternative antigen formats, modified screening criteria, additional candidate evaluation, or revised assay development strategy. Milestone-based communication helps you make informed decisions before committing to additional work.